Celldex Therapeutics, Inc

Celldex announced positive long-term Phase 2 results for barzolvolimab in chronic spontaneous urticaria (CSU), showing that up to 64% of patients remained angioedema-free seven months after treatment completion. The drug demonstrated rapid, significant, and durable improvements in angioedema symptoms, with potential to shift CSU treatment from sy...

Celldex announced positive Phase 1 results for CDX-622, a novel bispecific antibody targeting soluble SCF and TSLP for inflammatory diseases. The drug demonstrated rapid, dose-dependent reductions in serum tryptase indicative of mast cell depletion and was well-tolerated at all dose levels. CDX-622 is now being studied in Phase 1b for mild to mod...

Celldex Therapeutics successfully closed an underwritten public offering of 11,896,750 shares of common stock at $29.00 per share, generating approximately $345 million in gross proceeds. The underwriters exercised their full option to purchase an additional 1,551,750 shares. The offering was managed by Leerink Partners, TD Cowen, Guggenheim Secu...

Celldex Therapeutics priced an underwritten public offering of 10.3 million shares at $29.00 per share, expecting to raise approximately $300 million in gross proceeds. The company plans to use the funds for commercial readiness and launch of barzolvolimab for CSU treatment, clinical development of product candidates, and expansion of its bispeci...

Celldex presented Phase 2 data showing barzolvolimab retreatment achieves similar efficacy to initial treatment in cold urticaria and symptomatic dermographism patients, with 62% and 60% complete response rates respectively. The data supports an intermittent treatment paradigm and barzolvolimab's profile as a first-in-class therapy. Phase 3 trial...